Comparing intervention to lower systolic blood pressure in chronic kidney disease (CKD): a cluster randomised trial (CRT)

ISRCTN	ISRCTN56023731
DOI	https://doi.org/10.1186/ISRCTN56023731
Secondary identifying numbers	7395/4843 (HF)

Submission date: 21/05/2008
Registration date: 12/06/2008
Last edited: 03/07/2014

Recruitment status: No longer recruiting
Overall study status: Completed
Condition category: Urological and Genital Diseases

Prospectively registered

Protocol

Statistical analysis plan

Results

Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Prof Simon deLusignan
Scientific

Department in Health Care
Management and Policy
University of Surrey
Guildford
GU2 7XH
United Kingdom

Study information

Study design	A two-year three-armed cluster randomised trial
Primary study design	Interventional
Secondary study design	Randomised controlled trial
Study setting(s)	GP practice
Study type	Quality of life
Scientific title
Study acronym	QI CKD
Study objectives	This cluster randomised trial (CRT) will compare two well-established quality improvement interventions with usual practice. The two intervention arms are: 1. Provision of clinical practice guidelines with prompts 2. Audit-based education
Ethics approval(s)	Ethics approval received from the Oxford Research Ethics Committee (Committee C) on the 31st October 2006 (ref: 07/H0606/141).
Health condition(s) or problem(s) studied	Chronic kidney disease
Intervention	The three interventions are: 1. Usual practice: a minimum of contacts will be made of these practices other than for data collection (n = 35 practices) 2. Distribution of clinical practice guidelines with prompts: this is an established, low cost method. It will provide a benchmark with which the effectiveness of other quality improvement interventions can be compared. We will develop a consensus between the study team, our expert advisory group and external peer reviewers', and produce appropriate guidance for the management of CKD in primary care. We will use the "Appraisal of Guidelines Research and Evaluation" (AGREE) instrument do to this. AGREE is a validated guideline development tool. This guidance will be distributed to practices with quarterly updates/reminders (n = 35 practices). In addition practices will have access to a supportive website with information about CKD, frequently asked questions (FAQs) and tools to improve CKD management. 3. Audit-based education: in addition to clinical practice guidelines, practices will receive six-monthly detailed comparative feedback about their quality of CKD management (n = 35 practices) The total duration of the intervention is two years.
Intervention type	Other
Primary outcome measure	The reduction of systolic blood pressure in hypertensive people with stage 3 to 5 chronic kidney disease according to the agreed target. The measure of primary and secondary outcome measures will take place at t = 0 (baseline), t = 1 year and t = 2 years.
Secondary outcome measures	Clinical and laboratory markers: 1. Recording and management of key co-morbidities: 1.1. Diabetes and its complications 1.2. Ischaemic heart disease 1.3. Heart failure 1.4. Obstruction/lower urinary tract symptoms 2. Recording and management of other cardiovascular risk factors: 2.1. Smoking status 2.2. Lipid management 2.3. Proteinuria 2.4. Anaemia 2.5. Glycated haemoglobin and microalbuminuria in people with diabetes mellitus 3. Serial measures of serum creatinine concentration and estimated glomerular filtration rate (GFR) 4. Avoiding harm. We wish to collect data to monitor whether blood pressure reduction is associated with an increased number of falls particularly in older people. Most people with CKD are elderly and at potential risk of falls. Notwithstanding the results of recent systematic reviews which failed to show an association between falls and anti-hypertensive medication, this possibility remains a genuine concern to some practitioners, and one that we propose to examine. A falls dataset will be devised and integrated into the renal dataset. We will investigate the relationship with use of angiotensin converting enzymes (ACE) inhibitors and angiotensin II receptor blockers and systolic blood pressure below 120 in CKD. 5. Practitioner confidence to be measured at t = 0, t = 1 year, and at end of project 6. Medicines management: 6.1. Use of drugs/therapy which affect renal function (for example non-steroidal anti-inflammatory drugs) 6.2. Use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers to control hypertension 6.3. Recording of medicines possession ratio based on days prescribed therapy as an index of concordance with anti-hypertensive therapy The measure of primary and secondary outcome measures will take place at t = 0 (baseline), t = 1 year and t = 2 years.
Overall study start date	01/04/2007
Completion date	01/04/2010

Eligibility

Participant type(s)	Patient
Age group	Adult
Sex	Both
Target number of participants	105 GP practices
Key inclusion criteria	The primary research participants are general practitioners involved in the study who will receive the various quality improvement interventions listed below. The interventions will be implemented at the practice (cluster) rather than the individual level. The study subjects (who may be regarded as secondary participants) will be all individuals with chronic kidney disease within the study practices. Inclusion criteria: 1. Practices who provide written consent to participate 2. Locality specialist who will support the participation of the practice and the implementation of standard guidelines across the participating practices (appropriate to the arm of the study they are involved in) 3. Primary Care Trust (PCT) commissioners' engagement with the project and willingness to consider learning from its findings 4. Practice has had the same computer system for the last five years and has no plans to change it, or will allow access to check data quality 5. Practice has electronic laboratory links for the last three years
Key exclusion criteria	1. Practices in whom the computing system has changed over the last five years 2. Practices lacking an appropriate computer system from which data can be extracted 3. Practices in which referral data (from primary care to secondary care) is not available
Date of first enrolment	01/04/2007
Date of final enrolment	01/04/2010

Locations

Countries of recruitment

England
United Kingdom

Study participating centre

Department in Health Care

Guildford
GU2 7XH
United Kingdom

Sponsor information

St George's University of London (UK)
University/education

Research and Development Office
Cranmer Terrace
London
SW17 0RE
England
United Kingdom

Phone	+44 (0)20 8725 5661
Email	slusigna@sgul.ac.uk
Website	http://www.sgul.ac.uk
"ROR"	https://ror.org/040f08y74

Funders

Funder type

Charity

The Health Foundation (UK) (ref: 7395/4843 (HF))

No information available

Kidney Research (UK) (ref: CDK/2007)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to share	No
IPD sharing plan summary	Not provided at time of registration
Publication and dissemination plan	Not provided at time of registration
IPD sharing plan

Study outputs

Output type	Details	Date created	Peer reviewed?	Patient-facing?
Results article	results	25/01/2013	Yes	No
Other publications	cross-sectional analysis	25/02/2013	Yes	No
Results article	results	10/09/2013	Yes	No